N-[6-(3-Amino-propoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide | 329925-15-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[6-(3-Amino-propoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
• 英文别名: p-tert.-butyl-N-[6-(3-aminopropoxy)-5-(o-methoxyphenoxy)-2-cyclopropyl-4-pyrimidinyl]benzene-sulfonamide；N-[6-(3-aminopropoxy)-2-cyclopropyl-5-(2-methoxyphenoxy)pyrimidin-4-yl]-4-tert-butylbenzenesulfonamide
• CAS: 329925-15-7
• 化学式: C₂₇H₃₄N₄O₅S
• 分子量: 526.657
• InChiKey: XFANFSOXNDYLLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-噻吩磺酰氯 、 N-[6-(3-Amino-propoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide 以to give 144 mg p-tert.-butyl-N-[6-(3-(2-thiophene-sulfonylamino)-propoxy)-5-(o-methoxyphenoxy)-2-cyclopropyl-4-pyrimidinyl]benzene-sulfonamide的产率得到4-tert-butyl-N-[6-(3-(2-thiophenesulfonylamino)-propoxy)-5-(o-methoxyphenoxy)-2-cyclopropyl-4-pyrimidinyl]-benzene-sulfonamide
  参考文献：
  名称：

  6 alkoxy-4-pyrimidinyl bis-sulfonamides

  摘要：

  本发明涉及一种新型双磺酰胺，例如以下式I所示的双磺酰胺及其纯对映异构体、对映异构体混合物、对映异构体外消旋体混合物和中间体形式以及其药学上可接受的盐，其中R1代表芳基；芳基-较低烷基；芳基-较低烯基；杂环芳基；或杂环芳基-较低烷基；R2代表较低烷基；三氟甲基；较低烷氧-较低烷基；较低烯基；较低炔基；芳基；芳基-较低烷基；芳基-较低烯基；杂环基；杂环基-较低烷基；杂环芳基；杂环芳基-较低烷基；环烷基；或环烷基-较低烷基。本发明还涉及一种制造这些化合物的方法，以及含有该化合物作为内皮素拮抗剂的制药组合物和使用本发明化合物治疗涉及内皮素的疾病的方法。

  公开号：

  US06596719B1
• 作为产物：
  描述：

  4,6-dichloro-5-(2-methoxyphenoxy)-2-cyclopropyl-pyrimidine 在 sodium hydride 作用下， 以 四氢呋喃 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[6-(3-Amino-propoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
  参考文献：
  名称：

  Bis-sulfonamides as endothelin receptor antagonists

  摘要：

  Modification of the structure of bosentan 1, the first marketed endothelin receptor antagonist (Tracleer(TM)), by introduction of a second sulfonamide function at the alkoxy side chain, led to bis-sulfonamides 2. This allowed to prepare dual ETA/ETB as well as ETB receptor selective antagonists, which could serve as tools to investigate the pharmacological consequences of selective ETB receptor blockade. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01083-1

文献信息

• 6 alkoxy-4-pyrimidinyl bis-sulfonamides
  申请人：Actelio Pharmaceuticals Ltd.

  公开号：US06596719B1

  公开（公告）日：2003-07-22

  The present invention relates to novel bis-sulfonamides represented, for example, by formula I below and a pure diastereomer, a mixture of diastereomers, a diastereomeric racemate, a mixture of diastereomeric racemates and meso-forms and a pharmaceutically acceptable salt thereof, wherein R1 represents aryl; aryl-lower alkyl; aryl-lower alkenyl; heteroaryl; or heteroaryl-lower alkyl; and R2 represents lower alkyl; trifluoromethyl; lower alkoxy-lower alkyl; lower alkenyl; lower alkynyl; aryl; aryl-lower alkyl; aryl-lower alkenyl; heterocyclyl; heterocyclyl-lower alkyl; heteroaryl; heteroaryl-lower alkyl; cycloalkyl; or cycloalkyl-lower alkyl. The present invention also relates to a process for manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the invention.

  本发明涉及一种新型双磺酰胺，例如以下式I所示的双磺酰胺及其纯对映异构体、对映异构体混合物、对映异构体外消旋体混合物和中间体形式以及其药学上可接受的盐，其中R1代表芳基；芳基-较低烷基；芳基-较低烯基；杂环芳基；或杂环芳基-较低烷基；R2代表较低烷基；三氟甲基；较低烷氧-较低烷基；较低烯基；较低炔基；芳基；芳基-较低烷基；芳基-较低烯基；杂环基；杂环基-较低烷基；杂环芳基；杂环芳基-较低烷基；环烷基；或环烷基-较低烷基。本发明还涉及一种制造这些化合物的方法，以及含有该化合物作为内皮素拮抗剂的制药组合物和使用本发明化合物治疗涉及内皮素的疾病的方法。
• BIS-SULFONAMIDES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1137642A1

  公开（公告）日：2001-10-04
• US6596719B1
  申请人：——

  公开号：US6596719B1

  公开（公告）日：2003-07-22
• [EN] BIS-SULFONAMIDES<br/>[FR] BIS-SULFONAMIDES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2001017976A1

  公开（公告）日：2001-03-15

  The invention relates to novel bis-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin antagonists.
• Bis-sulfonamides as endothelin receptor antagonists
  作者：Christoph Boss、Martin H Bolli、Thomas Weller、Walter Fischli、Martine Clozel

  DOI：10.1016/s0960-894x(02)01083-1

  日期：2003.3

  Modification of the structure of bosentan 1, the first marketed endothelin receptor antagonist (Tracleer(TM)), by introduction of a second sulfonamide function at the alkoxy side chain, led to bis-sulfonamides 2. This allowed to prepare dual ETA/ETB as well as ETB receptor selective antagonists, which could serve as tools to investigate the pharmacological consequences of selective ETB receptor blockade. (C) 2003 Elsevier Science Ltd. All rights reserved.